Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells As a Candidate Universal Influenza Vaccine

Overview

Journal Front Bioeng Biotechnol

Date 2015 Dec 24

PMID 26697423

Citations 15

Authors

Sandiswa Mbewana

Elizabeth Mortimer

Francisco F P G Pera

Inga Isabel Hitzeroth

Edward P Rybicki

Affiliations

Soon will be listed here.

Abstract

The spread of influenza A viruses is partially controlled and prevented by vaccination. The matrix protein 2 ectodomain (M2e) is the most conserved sequence in influenza A viruses, and is therefore a good potential target for a vaccine to protect against multiple virus subtypes. We explored the feasibility of an M2e-based universal influenza A vaccine candidate based on the highly pathogenic avian influenza A virus, H5N1. A synthetic M2e gene was human- and plant-codon optimized and fused in-frame with a sequence encoding the N-terminal proline-rich domain (Zera(®)) of the γ-zein protein of maize. Zera(®)M2e was expressed transiently in Nicotiana benthamiana and Sf21 baculovirus/insect cell expression systems, and Zera(®)M2e protein bodies (PBs) were successfully produced in both expression systems. The plant-produced Zera(®)M2e PBs were purified and injected into Balb/c mice. Western blot analysis using insect cell-produced Zera(®)M2e PBs and multiple tandem M2e sequences (5xM2e) fused with the avian influenza H5N1 transmembrane and cytosolic tail (5xM2e_tHA) confirmed the presence of M2e-specific antibodies in immunized mice sera. The immunogenicity of the Zera(®)M2e indicates that our plant-produced protein has potential as an inexpensive universal influenza A vaccine.

Citing Articles

Modeling coding sequence design for virus-based expression in tobacco.

Burghardt M, Tuller T Synth Syst Biotechnol. 2025; 10(2):337-345.

PMID: 39802156 PMC: 11718241. DOI: 10.1016/j.synbio.2024.12.002.

Tobacco as bioenergy and medical plant for biofuels and bioproduction.

Shen K, Xia L, Gao X, Li C, Sun P, Liu Y Heliyon. 2024; 10(13):e33920.

PMID: 39055830 PMC: 11269859. DOI: 10.1016/j.heliyon.2024.e33920.

Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.

Malik S, Asghar M, Waheed Y Vaccine X. 2024; 17:100452.

PMID: 38328274 PMC: 10848012. DOI: 10.1016/j.jvacx.2024.100452.

Recent advances in expression and purification strategies for plant made vaccines.

Venkataraman S, Khan I, Habibi P, Le M, Lippert R, Hefferon K Front Plant Sci. 2023; 14:1273958.

PMID: 38078091 PMC: 10701439. DOI: 10.3389/fpls.2023.1273958.

Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems.

Tiwari P, Srivastava Y, Sharma A, Vinayagam R Life (Basel). 2023; 13(9).

PMID: 37763279 PMC: 10532476. DOI: 10.3390/life13091875.

References

Jegerlehner A, Schmitz N, Storni T, Bachmann M . Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172(9):5598-605. DOI: 10.4049/jimmunol.172.9.5598. View

Huleatt J, Jacobs A, Tang J, Desai P, Kopp E, Huang Y . Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine. 2006; 25(4):763-75. DOI: 10.1016/j.vaccine.2006.08.013. View

Webster R, BEAN W, Gorman O, Chambers T, Kawaoka Y . Evolution and ecology of influenza A viruses. Microbiol Rev. 1992; 56(1):152-79. PMC: 372859. DOI: 10.1128/mr.56.1.152-179.1992. View

Ionescu R, Przysiecki C, Liang X, Garsky V, Fan J, Wang B . Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J Pharm Sci. 2005; 95(1):70-9. DOI: 10.1002/jps.20493. View

Petukhova N, Gasanova T, Stepanova L, Rusova O, Potapchuk M, Korotkov A . Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Curr Pharm Des. 2013; 19(31):5587-600. DOI: 10.2174/13816128113199990337. View

Joseph M, Ludevid M, Torrent M, Rofidal V, Tauzin M, Rossignol M . Proteomic characterisation of endoplasmic reticulum-derived protein bodies in tobacco leaves. BMC Plant Biol. 2012; 12:36. PMC: 3342223. DOI: 10.1186/1471-2229-12-36. View

Wang L, Hess A, Chang T, Wang Y, Champion J, Compans R . Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine. 2013; 10(2):473-82. PMC: 3948190. DOI: 10.1016/j.nano.2013.08.005. View

Johansson B, Bucher D, POKORNY B, Mikhail A, KILBOURNE E . Identification of PR8 M1 protein in influenza virus high-yield reassortants by M1-specific monoclonal antibodies. Virology. 1989; 171(2):634-6. DOI: 10.1016/0042-6822(89)90638-7. View

Takeda A, Sugiyama K, Nagano H, Mori M, Kaido M, Mise K . Identification of a novel RNA silencing suppressor, NSs protein of Tomato spotted wilt virus. FEBS Lett. 2002; 532(1-2):75-9. DOI: 10.1016/s0014-5793(02)03632-3. View

10.

Mainieri D, Rossi M, Archinti M, Bellucci M, De Marchis F, Vavassori S . Zeolin. A new recombinant storage protein constructed using maize gamma-zein and bean phaseolin. Plant Physiol. 2004; 136(3):3447-56. PMC: 527144. DOI: 10.1104/pp.104.046409. View

11.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W . A "universal" human influenza A vaccine. Virus Res. 2004; 103(1-2):173-6. DOI: 10.1016/j.virusres.2004.02.030. View

12.

Mortimer E, Maclean J, Mbewana S, Buys A, Williamson A, Hitzeroth I . Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol. 2012; 12:14. PMC: 3358240. DOI: 10.1186/1472-6750-12-14. View

13.

Rossman J, Jing X, Leser G, Balannik V, Pinto L, Lamb R . Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J Virol. 2010; 84(10):5078-88. PMC: 2863831. DOI: 10.1128/JVI.00119-10. View

14.

Kaplan B, Webby R . The avian and mammalian host range of highly pathogenic avian H5N1 influenza. Virus Res. 2013; 178(1):3-11. PMC: 3922066. DOI: 10.1016/j.virusres.2013.09.004. View

15.

Black R, Rota P, Gorodkova N, Cramer A, Klenk H, Kendal A . Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J Gen Virol. 1993; 74 ( Pt 8):1673-7. DOI: 10.1099/0022-1317-74-8-1673. View

16.

Nemchinov L, Natilla A . Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expr Purif. 2007; 56(2):153-9. DOI: 10.1016/j.pep.2007.05.015. View

17.

Webster R, Govorkova E . H5N1 influenza--continuing evolution and spread. N Engl J Med. 2006; 355(21):2174-7. DOI: 10.1056/NEJMp068205. View

18.

Rybicki E . Plant-produced vaccines: promise and reality. Drug Discov Today. 2008; 14(1-2):16-24. DOI: 10.1016/j.drudis.2008.10.002. View

19.

Holsinger L, Lamb R . Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology. 1991; 183(1):32-43. DOI: 10.1016/0042-6822(91)90115-r. View

20.

DAoust M, Lavoie P, Couture M, Trepanier S, Guay J, Dargis M . Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008; 6(9):930-40. DOI: 10.1111/j.1467-7652.2008.00384.x. View